Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s disease ; volume:20 ; number:1 ; day:22 ; month:6 ; year:2023 ; pages:1-14 ; date:12.2023
Journal of neuroinflammation ; 20, Heft 1 (22.6.2023), 1-14, 12.2023
- Urheber
-
Amo-Aparicio, Jesus
Daly, Jonathan
Højen, Jesper Falkesgaard
Dinarello, Charles A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12974-023-02830-w
- URN
-
urn:nbn:de:101:1-2023092508182559295771
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Amo-Aparicio, Jesus
- Daly, Jonathan
- Højen, Jesper Falkesgaard
- Dinarello, Charles A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
Loss of Drosha underlies dopaminergic neuron toxicity in models of Parkinson’s disease
Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
AVE0991 ameliorates dopaminergic neuronal damage in Parkinson’s disease through HOTAIRM1/miR-223-3p/α-synuclein axis
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Association of Glial Activation and α-Synuclein Pathology in Parkinson’s Disease
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
Loss of Drosha underlies dopaminergic neuron toxicity in models of Parkinson’s disease
Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
AVE0991 ameliorates dopaminergic neuronal damage in Parkinson’s disease through HOTAIRM1/miR-223-3p/α-synuclein axis
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Association of Glial Activation and α-Synuclein Pathology in Parkinson’s Disease
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
Loss of Drosha underlies dopaminergic neuron toxicity in models of Parkinson’s disease
Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
AVE0991 ameliorates dopaminergic neuronal damage in Parkinson’s disease through HOTAIRM1/miR-223-3p/α-synuclein axis
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model